Clinical Trial Update: A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating whether adding rucaparib to enzalutamide improves outcomes for men with metastatic castration-resistant prostate cancer t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)
• Rucaparib (rucaparib)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING